Back to Search Start Over

Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions.

Authors :
Moquin-Beaudry G
Benabdallah B
Maggiorani D
Le O
Li Y
Colas C
Raggi C
Ellezam B
M'Callum MA
Dal Soglio D
Guimond JV
Paganelli M
Haddad E
Beauséjour C
Source :
Cell reports methods [Cell Rep Methods] 2022 Jan 14; Vol. 2 (1), pp. 100153. Date of Electronic Publication: 2022 Jan 14 (Print Publication: 2022).
Publication Year :
2022

Abstract

Modeling the tumor-immune cell interactions in humanized mice is complex and limits drug development. Here, we generated easily accessible tumor models by transforming either primary skin fibroblasts or induced pluripotent stem cell-derived cell lines injected in immune-deficient mice reconstituted with human autologous immune cells. Our results showed that fibroblastic, hepatic, or neural tumors were all efficiently infiltrated and partially or totally rejected by autologous immune cells in humanized mice. Characterization of tumor-immune infiltrates revealed high expression levels of the dysfunction markers Tim3 and PD-1 in T cells and an enrichment in regulatory T cells, suggesting rapid establishment of immunomodulatory phenotypes. Inhibition of PD-1 by Nivolumab in humanized mice resulted in increased immune cell infiltration and a slight decrease in tumor growth. We expect that these versatile and accessible cancer models will facilitate preclinical studies and the evaluation of autologous cancer immunotherapies across a range of different tumor cell types.<br />Competing Interests: The authors have no conflicts of interest to disclose. C.R. and M.P. are co-founders, shareholders, and officers of the regenerative medicine company Morphocell Technologies, Inc.<br /> (© 2021 The Authors.)

Details

Language :
English
ISSN :
2667-2375
Volume :
2
Issue :
1
Database :
MEDLINE
Journal :
Cell reports methods
Publication Type :
Academic Journal
Accession number :
35474871
Full Text :
https://doi.org/10.1016/j.crmeth.2021.100153